Proteomic data in meningiomas: post-proteomic analysis can reveal novel pathophysiological pathways

Area of Science:

• Neuro-oncology
• Proteomics
• Systems Biology

Background:

• Meningiomas represent approximately 20% of adult primary intracranial tumors.
• While WHO I meningiomas are typically benign, they can progress to higher grades (WHO II/III).
• Understanding meningioma progression pathways is crucial for improved diagnostics and therapeutics.

Purpose of the Study:

• To systematically review shotgun proteomic analyses of meningiomas.
• To identify proteins and pathways associated with meningioma grade progression.
• To provide insights into meningioma pathophysiology through network analysis.

Main Methods:

• Systematic review of seven independent shotgun proteomic studies on meningiomas.
• Network analysis of differentially expressed proteins between WHO I and WHO II meningiomas.
• Validation of core network components using Western blot analysis.

Main Results:

• Identified 15 proteins differentiating WHO I from WHO II meningiomas and 9 proteins differentiating WHO II from WHO III meningiomas.
• Network analysis generated a hypothesis for protein involvement in meningioma progression.
• Western blot analysis supported a core network including VDAC2, APOA1, and HNF4α, despite tissue analysis challenges.

Conclusions:

• Systematic review and network analysis offer valuable insights into meningioma pathophysiology.
• Despite inherent difficulties in proteomic and biochemical analysis of meningiomas, key protein networks implicated in progression were identified.
• Further research into these identified protein networks may lead to novel diagnostic and therapeutic strategies for meningioma.